456 Studies Now Enrolling
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (ALPINE)
| Sponsor: | BeiGene, Ltd. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAS2723 |
| U.S. Govt. ID: | NCT03734016 |
| Contact: | Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to find out if the study drug zanubrutinib is safe and can help subjects who have Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). This will involve comparison of two drugs, zanubrutinib and ibrutinib, in treating CLL/SLL by: (1)Testing how effectively the drug zanubrutinib controls CLL/SLL and (2) Comparing the side effects of each of the drugs.
This study is closed
Do You Qualify?
| Are you age 18 or older? | Yes | No |
| Do you have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)? | Yes | No |
| Have you relapsed or had an ineffective result to at least 1 prior systemic therapy for CLL or SLL? | Yes | No |
| Is your life expectancy 6 months? | Yes | No |